Rizatriptan

Rizatriptan

Clinical data
Trade names	Maxalt
AHFS/Drugs.com	Monograph
MedlinePlus	a601109
Pregnancy category	B1 (Au), C (U.S.)
Routes of administration	Oral
ATC code	N02CC04 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability	45%
Protein binding	14%
Metabolism	by monoamine oxidase
Biological half-life	2–3 hours
Excretion	82% urine; 12% faeces
Identifiers
IUPAC name N,N-dimethyl-2-[5-(1H-1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
CAS Number	145202-66-0 Y
PubChem CID	5078
IUPHAR/BPS	51
DrugBank	DB00953 Y
ChemSpider	4900 Y
UNII	WR978S7QHH
KEGG	D00675 N
ChEBI	CHEBI:48273 Y
ChEMBL	CHEMBL905 Y
ECHA InfoCard	100.119.030
Chemical and physical data
Formula	C15H19N5
Molar mass	269.345 g/mol
3D model (Jmol)	Interactive image
SMILES n1cn(nc1)Cc2cc3c(cc2)ncc3CCN(C)C
InChI InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3 Y Key:ULFRLSNUDGIQQP-UHFFFAOYSA-N Y
NY (what is this?)

Rizatriptan (trade name Maxalt) is a 5-HT₁ receptor agonist of the triptan class of drugs developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the United States Food and Drug Administration (FDA) on June 29, 1998. It is a second-generation triptan.

Rizatriptan is available only by prescription in Australia, Finland, the United States, Canada and New Zealand. Similarly, it is classed as a POM (Prescription Only Medicine) in the United Kingdom, Italy (as Rizaliv), France, Israel (as Rizalt), The Netherlands, Croatia and Spain (as Maxalt).

Rizatriptan is FDA-approved to treat acute migraine attacks with or without aura. It does not prevent future migraine attacks. Rizatriptan is also used off-label to treat cluster headaches.

Severe:

Atypical sensations:

Cardiovascular:

Ear, nose, and throat:

Gastrointestinal:

Muscular:

Neurological:

Respiratory: